Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to measure the efficacy of solifenacin succinate
(VESIcare) on treating urinary incontinence in Parkinson's disease patients.
The secondary objective of this study is to examine the effect of solifenacin succinate
(VESIcare) on symptoms of PD and the patient's quality of life.